That is what makes the Digital Health & AI Innovation Summit (DHAI), taking place June 8-9 in Boston, distinctive within an increasingly competitive field of AI and innovation conferences. The Summit certainly offers a high-caliber program and noted speakers. However, its real value proposition beyond the agenda lies in the conversations and takeaways.

The carefully curated forum, organized by Amir Lahav, PhD, and World BI, is intentionally designed for a smaller community of roughly 500 attendees and more than 150 speakers and innovators. The result is that the connections become as valuable as the presentations.

That distinction matters more than many realize.

Artificial intelligence and digital health are moving at extraordinary speed. Health systems, pharmaceutical companies, regulators, investors and technology innovators are all trying to answer the same questions: How do we apply innovation responsibly while improving outcomes for patients and clinicians? How do we integrate AI into the R&D process? How can we leverage information technologies to accelerate the recruitment of the right people for clinical trials? The challenge is no longer simply technological capability. The challenge is implementation, governance and integration into the realities of care delivery.

Those questions are difficult to answer from the back row of a ballroom.

They are more likely to be explored over coffee between sessions, during a shared meal, or in quieter moments when people can challenge assumptions, exchange experiences and discuss what is actually working in health systems, research environments, and patient care settings.

That is where DHAI distinguishes itself.

The Power of Curated Expertise

What gives a conference enduring value is not only the quality of its speakers, but whether those speakers remain accessible enough to challenge assumptions, answer difficult questions and engage in unscripted dialogue. That is increasingly uncommon in modern health conferences, where influence often feels managed from a distance.

At DHAI, the proximity to the experience of 150 presenters is intentional.

The next era of health won’t be built in silos and it certainly won’t be forged by focusing on the hype. It requires leaders willing to share their failures alongside their successes, and their fears alongside their visions,” shares Amir Lahav, PhD, curator and DHAI organizer. “The DHAI Summit provides an exclusive, trusted space for these unfiltered conversations that rarely happen on public stages. This is an exclusive invitation to join the health AI  pioneers who are moving the needle and step into the room where the real trajectory of medicine is being shaped,” he adds.

For attendees seeking to understand how artificial intelligence is moving from experimentation to clinical reality, few conversations may prove more valuable than those surrounding the work of Dr. Dennis Wall at Stanford University. His groundbreaking efforts to apply AI to accelerate diagnostics, particularly in neurological and developmental conditions, reflect the growing intersection of machine learning and patient-centered medicine. In most settings, hearing someone like Wall speak might last 20 minutes. Here, the opportunity to continue the discussion between sessions may be equally important as the presentation itself.

The same can be said for leaders shaping the future of pharmaceutical innovation through AI. Thomas Fuchs, Chief AI Officer at Eli Lilly and Company, operates at the center of one of the most significant transformations underway in life sciences. His work integrating AI, pathology and drug discovery reflects how computational science is redefining therapeutic development. With pharmaceutical companies investing billions into AI-enabled research ecosystems, the ability to exchange perspectives directly with someone navigating those realities daily carries extraordinary value.

Precision medicine also takes on a more practical dimension through leaders such as John Axerio-Cilies, Chief Data and Technology Officer at Tempus AI. Tempus has become emblematic of how data science, oncology and artificial intelligence are beginning to reshape personalized medicine and diagnostics. Yet the real insight often comes not from keynote slides but from candid reflections on implementation challenges, physician adoption, workflow integration, and trust in AI-driven systems.

What also distinguishes the program is its recognition that health innovation no longer lives within traditional boundaries. Biology, computational science, organizational leadership and entrepreneurship are rapidly converging, creating entirely new expectations for how innovation enters the health ecosystem.

That reality becomes especially clear when considering trusted voices such as Tom Lawry, author of Hacking Healthcare and one of the most respected global advisors on AI strategy in health. For years, Lawry has argued that artificial intelligence alone cannot transform the delivery of care. Institutions themselves must evolve alongside technology. Leadership structures, workflow, culture and decision-making all become part of the innovation equation. His perspective reinforces an increasingly important truth: AI implementation is not fundamentally a technology challenge. It is a human challenge.

That same intersection between innovation and execution is reflected in the participation of Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups. Her work focuses on helping emerging companies move beyond promising ideas toward scalable and commercially viable solutions. Through strategy development, technical enablement and go-to-market support, she works directly with startups navigating the increasingly complex realities of AI, digital health and life sciences innovation. At a time when thousands of companies are entering the AI marketplace, Frank brings an unusually practical understanding of what separates experimentation from sustainable impact across the global health ecosystem.

The scientific and technical dimensions of the Summit are equally compelling. Arturo Loaiza-Bonilla, MD, MSEd, Co-Founder and Chief Medical AI Officer of Massive Bio, Network Chief of Hematology and Oncology at St. Luke’s University Health Network, whom I met recently during HITLAB Health Innovation Week in New York, champions an important evolution in medicine, where clinical leadership, oncology, data science and AI innovation are interconnected. His work sits at the intersection of precision medicine, clinical trials and responsible AI application, demonstrating how technology can expand access and support informed care decisions while keeping physicians and patients at the center of the experience.

The program also grounds innovation in the realities of patient care and health system operations. Through her leadership at NYC Health + Hospitals, Dr. Komal Bajaj has focused extensively on quality, equity and implementation within one of the nation’s largest public health systems. Her perspective introduces an important layer of realism into discussions that can sometimes become overly theoretical. AI may promise efficiency, but health systems must still ensure that innovation improves care delivery rather than complicates it.

That balance between aspiration and practicality is also reflected in leaders such as Lauren Li of Novartis, whose work in AI and innovation strategy demonstrates how global life sciences companies are integrating AI responsibly across research, development, and commercialization. The questions facing companies like Novartis are no longer whether AI will shape health innovation, but how to apply it responsibly while preserving scientific rigor and public trust.

Equally important to the DHAI agenda is the presence of Jeremy Walsh, Chief AI Officer at the Food and Drug Administration. At a moment when AI is moving rapidly into research, clinical decision support, diagnostics and operational health systems, regulatory leadership must provide oversight. FDA voice addresses a growing concern that innovation and governance cannot operate on separate tracks. The future of AI in health will depend not only on technological capability, but on transparency, accountability and safety. His perspective brings a policy and regulatory dimension to a conversation too often dominated by technology.

Taken together, these leaders represent more than expertise. They reflect the convergence of medicine, data science, biotechnology, health systems, patient engagement and policy. The global health ecosystem is entering a period in which barriers between disciplines are dissolving. Clinicians must understand data science. Technologists must better appreciate patient experience and the realities of workflow. Pharmaceutical leaders must think beyond molecules toward digital ecosystems and longitudinal patient engagement.

Why Human Connection Still Matters in the AI Era

That convergence changes the value of gatherings like this one. Large conferences often showcase these worlds side by side. Smaller curated forums create the possibility for those worlds to interact.

That dynamic is particularly important in digital health, where enthusiasm can sometimes outpace evidence. AI is neither a miracle nor a menace. It is a tool shaped by human intention, data quality and leadership. The most important conversations in AI and health today are not only about capability. They are about judgment.

How do we reduce physician burnout without depersonalizing medicine? How do we use predictive analytics responsibly? How do we ensure that innovation improves access rather than deepens disparities? How do we maintain trust while integrating increasingly autonomous technologies into patient care?

Those are conversations that require candor and mutual learning.

As someone attending and stepping to the stage during DHAI, I believe that may ultimately become its greatest differentiator. In health, relationships still matter. Communication still matters. Shared perspective still matters. Technology may accelerate insight, but human interaction remains essential to wisdom.

Health innovation does not advance through presentations alone. It advances through collaboration, challenge and conversation. Those exchanges between sessions often become the catalyst for strategies and unexpected ideas that continue long after this event comes to a close.

In a global health environment often defined by complexity, there is growing value in spaces where innovation feels ambitious and human. The DHAI appears designed to deliver that ROI.

The post The Value of Health AI Conferences Is No Longer the Stage. It’s the Hallway Conversation appeared first on Medika Life.

An operational model developed in Algeria may show a way that countries can make childhood vaccines more effective, more acceptable and more economical. It is a model that may provide a framework for middle-income countries across the globe, including many across the rest of Africa.

Six-in-one (or hexavalent) vaccines are cutting the number of clinic visits needed to prevent multiple life‑threatening infections and easing pressure on already stretched health systems. Growing economic evidence from Algeria and several Latin American countries suggests that while these vaccines may cost more upfront, the investment may be largely or entirely recovered through fewer appointments, streamlined logistics, and a reduction in cases of vaccine-preventable diseases and potential adverse events from vaccination. Yet the children who could benefit most – those living in low‑ and middle‑income countries are still the least likely to receive them, widening an avoidable gap between what modern vaccines can do and the protection children actually receive.

Most hexavalent vaccines save money in another way: they reduce the number of adverse events – side effects – that require treatment in a hospital or clinic. Acellular hexavalent vaccines include a type of protection against pertussis, or whooping cough, which is the gold standard for immunization in higher-income countries but has not yet been widely adopted beyond them.

With more than a decade of historical data supporting safety and efficacy, these acellular pertussis vaccines have a notable track record of improving vaccination coverage rates (VCR) and parents’ willingness to have their children protected, as they cause fewer painful adverse events [1].

Acellular pertussis (aP) vaccines are formulated using isolated antigens, which are purified and detoxified, thereby removing most of the components of the bacterium that cause undesirable reactions [2].

Most low- to middle-income countries still use whole-cell pertussis vaccines, which include a suspension of the entire inactivated Bordetella pertussis organism – some 3,000 antigens. Although the inclusion of far more antigens can result in a marginally higher immune response, the complexity of the vaccine leads to varying amounts of reaction-causing components between batches of vaccine and varying levels of protection [2].

The combination of more adverse events and variable efficacy means that developing countries bear a disproportionate share of the burden incurred through side effects. The side effects in children lead to an increased reluctance among parents to agree to future vaccines for their children and higher costs for the healthcare system. These problems often arise in healthcare systems that are inadequately equipped to deal with them.

Expert opinion from Algeria indicates that acellular hexavalent vaccination has improved vaccination coverage levels and simplified the vaccination schedule by reducing the number of appointments. It reduces the required number of immunization visits from ten to six. This eases pressure on overstretched health services, simplifies logistics and cold-chain management, and reduces indirect societal costs, including the time parents spend away from work.

Algeria is the third WHO African region country to adopt the acellular hexavalent vaccine into its national immunization schedule. Economic data from those countries and several in Latin America demonstrate that a rollout of the vaccine across African countries is not only possible but also economically advantageous [3,4,5,6].

Algeria’s vaccination metrics: an operational model for success

Vaccines have transformed child health in Algeria, as they have across the world. Since the initial introduction of vaccination in Algeria, followed by sustained efforts to expand the vaccination schedule, infant mortality rates have dropped dramatically from 163 per 1,000 live births in 1966 to 20 per 1,000 in 2023, a reduction of around 87% [7].

The percentage of children protected in Algeria has exceeded the targets set by the World Health Organization (WHO) for decades, with diphtheria, tetanus toxoid and pertussis (DTP) coverage consistently above 90% [8]. As in many countries, the COVID-19 pandemic disrupted healthcare systems, leading to a decline in vaccination rates, with DTP-3 coverage, a key measure of childhood vaccination, reduced to 77% in 2022 [9]. This situation was quickly improved, with coverage increasing to 92% by 2024 [9].

In 2022, three cases of polio caused by circulating vaccine-derived poliovirus type 2 were reported [10]. Rarely, the circulating vaccine-derived virus causes polio, highlighting the necessity of timely vaccination with IPV, with which these vaccine-derived cases do not occur [11].

The shift to hexavalent vaccination

Algeria’s shift from its former schedule to hexavalent vaccination was not a straightforward process. Initially, the five-in-one (or pentavalent) vaccine was replaced by a combination of the tetravalent vaccine (DTP-Hib) and the monovalent Hepatitis B vaccine (HBV), administered across 10 separate healthcare visits, necessitating additional appointments [12].

The change in the vaccination schedule resulted in delays in dose administration and a decrease in vaccination coverage. This issue was resolved with the introduction of the new schedule, which integrated an acellular hexavalent vaccine in 2023, reducing the number of required healthcare visits to six [13].

While polio vaccination was present in the previous schedule (with one IPV dose at 3 months and 3 OPV doses at 2, 4, and 12 months), inclusion as part of a hexavalent vaccine simplified the schedule (giving three doses of IPV at 2, 4, and 12 months associated with three OPV doses), helping to maintain the global strategy for polio eradication. The WHO recommends that all countries using OPV adopt a vaccination schedule with at least two doses of inactivated vaccine, which gives individual protection without the risk of vaccine-related polio [14].

The financial metrics of the switch

A recent whitepaper conducted a pharmacoeconomic analysis of the budgetary impact of transitioning from a whole-cell tetravalent vaccination schedule to an acellular hexavalent schedule. While the switch was associated with an increase in annual program expenditure of approximately 26 million Euros (around a 58% rise in upfront costs), this was substantially offset by nearly 19 million Euros in annual savings generated through the management of adverse events, improved logistics and transportation, and increased parental productivity [13]. Overall, roughly 73% of the upfront cost was offset by these savings.

Algeria is the latest in a series of examples where this is the case. The nominal, upfront cost of acellular hexavalent vaccines is typically higher than that of whole-cell vaccines; this has, in many cases, deterred countries from adopting them. However, there are many benefits at both the economic and systemic levels that recoup much of the costs of acellular hexavalent vaccines. In many instances, these costs are hidden and not factored into initial value calculations.

Similar experiences have been seen in other countries. In Argentina, Peru, and South Africa, the switch to hexavalent vaccines led to higher initial costs, but these were substantially offset by savings from fewer adverse events, lower programmatic expenses, and improved logistics. For example, in data from Argentina, roughly 90% of the initial investment into acellular hexavalent vaccines was recovered through fewer adverse event-associated costs and lower programmatic costs [15]. Peru reported a reduction in logistical costs by nearly 60%, with roughly 44% of the initial increase in costs recovered [16]. South Africa achieved overall savings of about 10 USD per child [3].

These calculations overlook benefits that are more difficult to quantify. For example, what costs are generated because of vaccines missed and infections caused by increased vaccine hesitancy on the part of parents. Across these settings, the higher upfront investment in hexavalent vaccines has proven to be economically viable, with much of the cost recouped through broader system efficiencies.

Programmatic benefits of hexavalent vaccination

Hexavalent vaccination offers the potential for simpler systems and higher levels of acceptance among patients. For the child, integrating six antigens into a single injection drastically reduces the number of needle sticks, alleviating injection-related anxiety and the prevalence of local reactions. This increases parental acceptance and helps to improve vaccination coverage.

Parents are relieved of the burden of coordinating multiple medical appointments, covering travel costs, and dealing with lost workdays. By reducing parental anxiety and the strain of repeated visits, combined vaccines help mitigate vaccine hesitancy within communities. This has been demonstrated in multiple studies across Africa, with investigations in Gambia and South Africa documenting concerns among parents about a child receiving more than two injections in a single visit [17,18]. Limiting the number of healthcare visits is also a crucial factor in increasing vaccine coverage in areas with limited healthcare infrastructure, such as those in rural southern Algeria.

For healthcare professionals, particularly in resource-limited settings such as rural areas in Africa, the adoption of combined vaccines helps to ease the administrative burden of multiple appointments. These formulations optimize consultation efficiency by drastically reducing the required administration time and simplifying inventory management [19].

The use of ready-to-use liquid vaccines, such as the hexavalents, has been shown to simplify and enhance the safety of the vaccination procedure when compared to vaccines that come as a powder that has to be reconstituted [20]. The preference for this approach among frontline workers is overwhelming: one study indicated that 97.6% of healthcare providers favored these liquid, combined formulations in their daily work [21]. Evidence supports this preference, demonstrating that the switch led to a dramatic reduction in administration errors (from 42.8% to 4%) and needlestick injuries (from 42.3% to 9.5%), while also yielding an average time savings of 1.1 minutes per dose [22].

The case for Hexavalent vaccination across Africa

Across the WHO Africa region, VCR has improved significantly over the last few decades; however, unfortunately, this improvement has stalled. The level of coverage for the third dose of DTP-containing vaccines, a standard benchmark for immunization system performance, has sat in the mid-70s for over a decade, with a current coverage of 76% [23].

This stagnation of the VCR is reflective of the ongoing issue of inequality. The gap in vaccine access runs not only between Africa and higher‑income regions, but also within the continent itself, where some countries consistently outperform others. Diseases, however, do not recognize borders; any outbreak that affects one country is likely to increase the risk to surrounding countries. Air travel enables a disease case to be spread to virtually any country in the world within just two days [24].

The COVID-19 pandemic was a clear example of the rapid spread in today’s world. Within a period of weeks, the virus spread from its origin in China to the entire globe, despite public health measures and lockdowns. With this in mind, any country that is falling behind on vaccination coverage becomes a weak link in a global chain where diseases can flourish and form reservoirs of cases that can allow diseases such as polio to spread unchecked.

Bringing vaccine equity to lower- and middle-income countries is therefore vital to addressing global health concerns. Hexavalent vaccination has demonstrated its ability to increase vaccine coverage in these countries. Among the WHO Africa region, Mauritius, which adopted hexavalent vaccination in 2017 [4] currently stands notably above the average for the region, with 96% coverage for the first dose of inactivated polio vaccine, and 93% for the benchmark based on DTP-containing vaccines [25].

Vaccine coverage translates into increased prosperity. Vaccination cannot be viewed as an inconvenient expense but as an investment. The WHO estimates that for every dollar spent, vaccination can yield a return on investment of around 54 USD – provided, of course, that the vaccines actually find their way into the arms of children [26].

As the Algerian case study demonstrates, higher upfront costs for acellular hexavalent      vaccines are often paid back by improvements in logistical efficiency, reduced healthcare burdens, and improved parental compliance. By bridging the gap between high- and low-income immunization standards through this investment, the life-saving benefits of gold standard vaccinations can become more than a privilege of geography, but a universal foundation for human health.

[This consensus paper is based on the findings of a white paper discussing the findings of a group of vaccination experts focusing on paediatric immunisation, supported by Sanofi. Intended for professional use.]

Reference list

1. Boisnard, F., Manson, C., Serradell, L., & Macina, D. (2023). DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure. Expert Review of Vaccines, 22(1), 1196–1213. https://doi.org/10.1080/14760584.2023.2280236
2. World Health Organization (2017) The immunological basis for immunization series: module 4: pertussis, update 2017. Available at: https://www.who.int/publications/i/item/the-immunological-basis-for-immunization-series-module-4-pertussis-update-2017
3. Batson A, Glassman A, Federgruen A, et al. The world needs to prepare now to prevent polio resurgence post eradication. BMJ Global Health. 2022;7(12):e011485. doi: https://doi.org/10.1136/bmjgh-2022-011485
4. ReliefWeb. Hexavalent vaccine: less injections and more protection babies. Available at: https://reliefweb.int/report/mauritius/hexavalent-vaccine-less-injections-and-more-protection-babies
5. Olivera, I., Grau, C., Dibarboure, H. et al. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine. BMC Health Serv Res 20, 295 (2020). https://doi.org/10.1186/s12913-020-05115-7
6. Romero M, Góngora D, Caicedo M. Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization

Value in Health Regional Issues, 2021; 26, 150-159

7. World Bank Data. Available at: https://data.worldbank.org/indicator/SP.DYN.IMRT.IN?locations=DZ
8. World Health Organization. Immunization data: African region. Available at: https://immunizationdata.who.int/dashboard/regions/african-region/DZA
9. World Health Organization.  DTP vaccination coverage. Available at: https://immunizationdata.who.int/global/wiise-detail-page/diphtheria-tetanus-toxoid-and-pertussis-(dtp)-vaccination-coverage?CODE=DZA&ANTIGEN=DTPCV3&YEAR=
10. GPEI – Algeria. Available at https://www.archive.polioeradication.org/where-we-work/algeria/
11. Global Polio Eradication Initiative. GPEI-OPV. polio global eradication initiative . Published 2016. Available at: https://polioeradication.org/polio-today/polio-prevention/the-vaccines/opv/           
12. Practical Implementation Guide for the 2016 National Immunization Schedule in Algeria. Available at: https://cnpm.org.dz/wp-content/uploads/2024/01/Guide_Pratique_de_Mise_en_Oeuvre_du_Nouveau_Calendrier_Natio-1.pdf
13. Laichour A, Kihel M, Aissaoui A, Olivera G. Pharmacoeconomic evaluation of national immunization program realisation in Algeria: cost-minimization analysis of switch from DTwP-Hib + HBV + IPV to an acellular hexavalent (DTaP-HBV-Hib-IPV) vaccine. Poster presented at: ISPOR Europe 2023; November 2023; Copenhagen, Denmark. Value in Health. 2023;26(Suppl 2):S2-EE134.
14. WHO Polio Position Paper 2022. Available at: https://www.who.int/publications/i/item/WHO-WER9725-277-300  
15. Olivera, I., Pérez, C.G., Lazarov, L. et al. Cost minimization analysis of a hexavalent vaccine in Argentina. BMC Health Serv Res 23, 1067 (2023). https://doi.org/10.1186/s12913-023-10038-0
16. Seinfeld J, Rosales ML, Sobrevilla A, López Yescas JG. Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru. BMC Health Serv Res. 2022 May 16;22(1):651. doi: 10.1186/s12913-022-08006-1. PMID: 35570278; PMCID: PMC9109284.
17. Idoko OT, Hampton LM, Mboizi RB, et al. Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine. Vaccine. 2016;34(41):5034-5039. doi: https://doi.org/10.1016/j.vaccine.2016.07.021
18. Hanani Tabana, Dudley L, Knight S, et al. The acceptability of three vaccine injections given to infants during a single clinic visit in South Africa. BMC Public Health. 2016;16(1). doi: https://doi.org/10.1186/s12889-016-3324-2
19. Pelissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care. 2000 Sep;6(9):1038-44.
20. Al-Bashir L, Ismail A, Aljunid SM. Parents‘ and healthcare professionals’ perception toward the introduction of a new fully liquid hexavalent vaccine in the Malaysian national immunization program: a cross-sectional study instrument development and its application. Front Immunol. 2023;14:1052450.
21. De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–82.
22. Esteve IC, Fernández PF, Palacios SL, Rodrı́guez MJ, Vino HP, Ortega BR, Nieto Nevot ML, Manch´on GD, L´opez-Belmonte J-L. Health care professionals’ preference for a fully liquid, ready-to-use hexavalent vaccine in Spain. Prev Med Rep. 2021;22:101376.
23. World Health Organization. Immunization data: African region. Available at: https://immunizationdata.who.int/dashboard/regions/african-region
24. Findlater A, Bogoch II. Human Mobility and the Global Spread of Infectious Diseases: A Focus on Air Travel. Trends Parasitol. 2018 Sep;34(9):772-783. doi: 10.1016/j.pt.2018.07.004. Epub 2018 Jul 23. PMID: 30049602; PMCID: PMC7106444.
25. World Health Organization. Immunization data: Mauritius. Available at: https://immunizationdata.who.int/dashboard/regions/african-region/MUS
26. World Health Organization (2025) Fully funded Gavi, the Vaccine Alliance, is a lifeline for child survival, says WHO. Available at: https://www.who.int/news/item/28-03-2025-fully-funded-gavi–the-vaccine-alliance–is-a-lifeline-for-child-survival–says-who

The post An Expert Perspective from Algeria on Hexavalent Vaccine Adoption appeared first on Medika Life.

Behind every budget shift lies a ripple effect, and today, global healthcare is at the receiving end. The result is shrinking access, rising costs, and widening inequities. The impact of geopolitical decisions is rarely confined to borders, it now extends into clinics, hospitals, and communities. What we are witnessing is not just a funding gap, but a structural shift in how the world values health.

The silent reallocation

Over the past years, global defense spending has surged to record levels. According to the Stockholm International Peace Research Institute (SIPRI), global military expenditure rose by 9.4% in real terms to $2718 billion in 2024, the highest global total ever recorded by SIPRI and the 10th year of consecutive increases. The total military expenditure accounted for 2.5% of the global gross domestic product (GDP) in 2024. These figures are expected to climb further following the June 2025 commitment by North Atlantic Treaty Organization (NATO) members to increase defence and security spending to 5% of GDP by 2035, more than twice the earlier 2% benchmark.

Meanwhile, public health budgets are being trimmed or stagnating. The World Health Organization (WHO) has raised serious concerns about the strain on global health systems, pointing to shrinking international aid and ongoing funding shortfalls. In February, Director-General Tedros Adhanom Ghebreyesus highlighted that abrupt and significant reductions in bilateral assistance have severely disrupted healthcare services across multiple countries, describing 2025 as “one of the most challenging years” in the organization’s history.

As per the WHO, an estimated 4.6 billion people worldwide still do not have access to essential health services, while around 2.1 billion experience financial strain due to healthcare expenses. Compounding this challenge, the global health workforce is projected to face a shortfall of 11 million professionals by 2030, with nurses accounting for more than half of this gap. When 4.6 billion people lack access to essential services, this is not only a development failure, but also a global stability risk – translating into fewer vaccinations, delayed disease surveillance, and weakened emergency response systems.

The global policy conversation increasingly treats defence spending as essential security investment. Health spending, however, is still framed as social expenditure rather than strategic infrastructure. This shift is particularly devastating for LMICs, where international aid often fills critical gaps.

Conflict and the collapse of care

Conflict has long been a stress test for health systems, but the consequences today are deeper and more far-reaching. As the Russia–Ukraine war entered its fifth year in 2026, Ukraine’s health system faced unprecedented strain, with attacks on healthcare rising nearly 20% in 2025 alone. Since the full-scale invasion began, the WHO has documented at least 2,881 attacks targeting hospitals, health workers, ambulances, and medical infrastructure, severely disrupting care delivery. Health outcomes have deteriorated sharply, with 59% of people in frontline areas reporting poor health, alongside surging mental health issues, cardiovascular conditions, and widespread lack of access to essential medicines. Intensified attacks in 2025, including a spike in strikes on medical warehouses, have further crippled supply chains.

In the aftermath of the war in Gaza, the region’s health system remains on the brink of collapse despite months of humanitarian efforts and intermittent pauses in fighting. Widespread damage to hospitals, severe shortages of medicines, and a surge in patients continue to overwhelm already fragile services. Many facilities operate at drastically reduced capacity, with critical treatments, including cancer care, meeting only a fraction of demand, while rising cases of skin and respiratory illnesses place further strain on the system. Healthcare workers, operating under extraordinary pressure and with limited resources, are struggling to manage overwhelming caseloads each day amid ongoing supply constraints and infrastructure damage. The crisis extends well beyond acute injuries, as patients with chronic illnesses face dangerous interruptions in care and deteriorating living conditions, turning access to healthcare into a daily struggle for survival.

Meanwhile, after three years of conflict, the Sudan war has evolved into the world’s largest humanitarian and health crisis, with 34 million people in need of aid and 21 million lacking access to basic healthcare. The system is collapsing under the combined weight of widespread disease outbreaks, acute malnutrition affecting over 4 million people, and relentless attacks on healthcare infrastructure—37% of facilities are now non-functional. As infectious diseases surge and funding falls short, Sudan’s health crisis continues to deepen, turning basic healthcare access into a matter of survival for millions.

What distinguishes the current moment is the scale of global interdependence. Earlier crises were largely contained within regions. Today, disruptions are transmitted across borders through tightly integrated supply chains, financing systems, and health workforces. The Ukraine conflict, for instance, has affected global pharmaceutical logistics and energy prices, indirectly increasing healthcare costs across Europe, Asia, and beyond. The result is not just localized breakdowns, but a systemic fragility in global health security.

Conflict as a cost multiplier in health delivery

Healthcare systems are tightly linked to global supply chains, making them highly vulnerable to geopolitical disruptions. When conflicts interrupt trade routes, restrict exports, or trigger sanctions, costs rise almost immediately, across pharmaceuticals, medical devices, and even basic supplies.

Energy shocks add further pressure. Hospitals, being energy-intensive, face higher operating costs as fuel and electricity prices climb. In conflict zones, even critical functions like vaccine cold chains and intensive care become difficult to sustain. The result is a steady increase in healthcare costs, one that is unevenly felt. While high-income countries may cushion the impact through insurance and subsidies, LMICs face a harsher reality, where rising out-of-pocket expenses can push millions into poverty.

At the same time, conflicts are driving up demand for care. Displacement, malnutrition, and infectious disease outbreaks are becoming more frequent, often compounded by climate-related crises. This creates a vicious cycle. Underfunded systems struggle to respond, outcomes worsen, and long-term costs escalate as preventable issues turn into full-blown crises.

Health communicators bridging gaps in a fragmented world

In times of systemic stress, communication becomes a strategic imperative. Health communicators are no longer just interpreters of science. They are interpreters of risk, resilience, and national preparedness. Their role is to translate complex realities into actionable understanding, to advocate for evidence-based decision-making, and to maintain trust in institutions. In today’s environment, narrative gaps are becoming policy gaps. When health is absent from security conversations, it is often absent from security budgets.

In the current context, communicators must:

• Elevate the narrative around health as a security priority, not a secondary concern.
• Highlight the human impact of budget cuts, moving beyond statistics to real stories.
• Counter misinformation proactively, especially in conflict-affected and resource-constrained settings.
• Support policy advocacy, ensuring that health remains central in national and global agendas.

Equally important is the need for communicators to adopt a more systems-oriented approach. This means connecting the dots between geopolitical decisions and health outcomes, helping stakeholders understand that these are deeply interconnected challenges. Investing in health is not just a moral imperative; it is an economic and strategic one. Strong health systems contribute to productivity, stability, and resilience. They are foundational to national security in the broadest sense.

Governments, multilateral organizations, private sector players, and civil society must come together to reassert the importance of health in the global agenda. Innovative financing mechanisms, public-private partnerships, and more efficient use of resources can help bridge funding gaps. But without political will, these solutions will remain insufficient.

If current trajectories persist, the consequences will extend far beyond strained health systems, they will reshape how societies absorb risk, respond to crises, and sustain economic stability. Healthcare cannot remain the residual line item in a world that is becoming more volatile, more interconnected, and more vulnerable. Narratives shape priorities, and priorities shape funding. If health continues to be framed as a cost rather than a cornerstone of resilience, it will keep losing ground to more immediate, visible threats. That framing must change urgently and decisively. Over the next decade, the countries that succeed in protecting population health will not necessarily be those spending the most on healthcare, but those most effectively integrating health into national security thinking. The real question before policymakers and global leaders is whether nations can remain economically stable, politically resilient, or socially secure while treating health as a

The post The Hidden Cost of Global Conflict: Why Health Security Is the First Casualty appeared first on Medika Life.

Suicide remains one of the leading causes of death in the United States, with young people particularly affected. These are not abstract figures. Each life lost represents a story interrupted, a family altered, and a community left to navigate grief and unanswered questions. Public health requires that we confront this reality not only with data, but with a commitment to building systems that respond to human experience in real time.

From Fragmentation to Continuity Across the Lifespan

For many years, suicide prevention in the United States has been shaped by dedicated organizations working across research, advocacy, education, and crisis response. The American Foundation for Suicide Prevention has played a central role in advancing scientific understanding, funding critical research, and advocating for national policy changes that recognize suicide as a preventable public health issue. Its work has helped elevate awareness, influence legislation, and bring suicide prevention into mainstream health conversations.

The Jed Foundation has taken a complementary path, focusing on upstream prevention by strengthening emotional health among adolescents and young adults. Through partnerships with high schools, colleges, and universities, JED has worked to embed mental health support within the environments where young people live and learn. Its programs have helped institutions move beyond reactive approaches toward more proactive models that build resilience, identify risk earlier, and foster a sense of belonging.

Each organization has demonstrated meaningful impact over time. Each has contributed to saving lives and shaping how mental health is understood. Their efforts, however, have largely operated within distinct domains. One has advanced national research and advocacy. The other has transformed youth and campus mental health systems. Both have addressed critical points along the continuum of care, yet the broader system has remained fragmented.

The decision to merge as equals reflects a recognition that suicide prevention cannot be addressed in silos. Public health challenges of this magnitude require continuity across the lifespan. Early emotional support, community-based intervention, crisis response, and long-term recovery must function as part of an integrated system rather than a series of disconnected efforts.

Connection, Not Scale Alone, Defines Public Health Impact

Public health is often described through infrastructure and policy. Those elements are essential, yet they are insufficient on their own. Public health is ultimately about connection. It connects evidence to action, systems to individuals, and care to lived experience.

Suicide prevention sits at the intersection of these connections. Risk is influenced by social conditions, access to care, stigma, and the environments in which people interact. Protective factors such as trusted relationships, purpose, and community support can alter outcomes when they are present and accessible. The challenge has not been a lack of understanding. The challenge has been delivering that understanding in ways that are coordinated, equitable, and sustained.

A unified organization has the potential to bridge long-standing gaps. It can align research with real-world application, ensuring that scientific insights inform programs that reach people earlier. It can connect youth-focused interventions with broader public awareness efforts, creating continuity rather than gaps as individuals move through different life stages. It can also strengthen advocacy by bringing together complementary perspectives into a more cohesive national voice.

Scale introduces both opportunity and responsibility. A larger organization can mobilize resources, influence policy, and expand reach. Public trust, however, is built in local and personal interactions. The effectiveness of this merger will depend on its ability to maintain proximity to individuals and communities while expanding its national impact. Size alone does not create connection. Intentional design does.

The combined organization is expected to operate with substantial resources, which creates an opportunity to accelerate progress. Resources must translate into accessible programs, stronger partnerships with schools and health systems, and tools that enable families, educators, and clinicians to act with confidence. Public health systems succeed when they reduce friction for those seeking help and make support visible before a crisis emerges.

This moment also offers a broader lesson for the health sector. Fragmentation is not unique to suicide prevention. Across chronic disease, health equity, and digital health, organizations often operate with shared purpose but limited alignment. The willingness of these two organizations to merge reflects an understanding that structural change may be necessary to achieve meaningful outcomes.

The integration process will require thoughtful leadership and a clear sense of purpose. Combining cultures, programs, and strategies requires discipline and humility. Success will not be measured by organizational scale or visibility. It will be measured by whether fewer individuals reach a point of crisis without support and whether more people experience a system that feels connected, responsive, and human.

Suicide is often described as preventable, which places responsibility on the systems designed to address it. Prevention requires more than awareness. It requires intentional coordination, early recognition, and sustained engagement across the continuum of care.

This merger does not resolve the complexity of suicide prevention. No single organization can. It does represent a meaningful step toward greater alignment in how society responds to one of its most pressing public health challenges. Connection is not an abstract ideal in public health. It is the foundation upon which progress depends.

For more information about both organizations, visit these organizations’ websites at afsp.org and jedfoundation.org. 

The post Suicide Prevention Is a Public Health Imperative, Not a Patchwork Effort appeared first on Medika Life.

This story also ran on NBC News. See below.

West Virginia’s Public Employees Insurance Agency enrolls nearly 215,000 people — state workers, as well as their spouses and dependents. The new law, which will take effect June 10, will allow plan members who have been approved for a course of treatment to pursue an alternative, medically appropriate treatment of equal or lesser value without the need for another approval from the state-based health plan.

“This legislation is rooted in a simple principle: if a treatment has already been approved, patients should be able to pursue a medically appropriate alternative without being forced to start the process over again — especially when it does not cost more,” Gov. Patrick Morrisey said in a statement after signing the bill into law on March 31.

“This is about common sense, compassion, and trusting patients and their doctors to make the best decisions for their care,” he said.

Delegate Laura Kimble, the Republican from Harrison County who introduced the legislation, told KFF Health News the measure offers “a rational solution” for patients facing “the most irrational and chaotic time of their lives.”

From Arizona to Rhode Island, at least half of all state legislatures have taken up bills this year related to prior authorization, a process that requires patients or their medical team to seek approval from an insurer before proceeding with care. These state efforts come as patients across the country await relief from prior authorization hurdles, as promised by dozens of major health insurers in a pledge announced by the Trump administration last year.

The West Virginia law was inspired by Eric Tennant, a coal-mining safety instructor from Bridgeport who died on Sept. 17 at age 58. In early 2025, the Public Employees Insurance Agency repeatedly denied him coverage of a $50,000 noninvasive cancer treatment, called histotripsy, that would have used ultrasound waves to target, and potentially shrink, the largest tumor in his liver. His family didn’t expect the procedure to eradicate the cancer, but they hoped it would buy him more time and improve his quality of life. The insurer said the procedure wasn’t medically necessary and that it was considered “experimental and investigational.”

Related coverage

After Series of Denials, His Insurer Approved Doctor-Recommended Cancer Care. It Was Too Late.

Eric Tennant’s doctors recommended histotripsy, which would target, and potentially destroy, a cancerous tumor in his liver. But by the time his insurer approved the treatment, Tennant was no longer considered a good candidate. He died in September. Read More

Becky Tennant, Eric’s widow, told members of a West Virginia House committee in late February that she submitted medical records, expert opinions, and data as part of several attempts to appeal the denial. She also reached out to “almost every one of our state representatives,” asking for help.

Nothing worked, she told lawmakers, until KFF Health News and NBC News got involved and posed questions to the Public Employees Insurance Agency about Eric’s case. Only then did the insurer reverse its decision and approve histotripsy, Tennant said.

“But by then, the delay had already done its damage,” she said.

Within one week of the reversal in late May, Eric Tennant was hospitalized. His health continued to decline, and by midsummer he was no longer considered a suitable candidate for the procedure. “The insurance company’s decision did not simply delay care. It closed doors,” his wife said.

Had the new law been in effect, Kimble said, Tennant could have undergone histotripsy without preapproval, because it was a less expensive alternative to chemotherapy, which his insurer had already authorized. The bill was passed unanimously by the state legislature in March.

U.S. health insurers argue that most prior authorization requests are quickly, if not instantly, approved. AHIP, the health insurance industry trade group, says prior authorization acts as an important guardrail in preventing potential harm to patients and reducing unnecessary health care costs. But denials and delays tend to affect patients who need expensive, time-sensitive care, studies have shown.

The practice has come under intense scrutiny in recent years, particularly after the fatal shooting of a health insurance executive in New York City in late 2024. Americans rank prior authorization as their biggest burden when it comes to getting health care, according to a poll published in February by KFF, a health information nonprofit that includes KFF Health News.

Samantha Knapp, a spokesperson for the West Virginia Department of Administration, would not answer questions about the law’s financial impact on the state. “We prefer to avoid any speculation at this time regarding potential impact or actions,” Knapp said.

In a fiscal note attached to the bill, Jason Haught, the Public Employees Insurance Agency’s chief financial officer, said the law would cost the agency an estimated $13 million annually and “cause member disruption.”

West Virginia isn’t an outlier in targeting prior authorization. By late 2025, 48 other states, in addition to the District of Columbia and Puerto Rico, already had some form of a prior authorization law — or laws — on the books, according to a report published in December by the National Association of Insurance Commissioners.

Many states have set up “gold carding” programs, which allow physicians with a track record of approvals to bypass prior authorization requirements. Some states establish a maximum number of days insurance companies are allowed to respond to requests, while others prohibit insurance companies from issuing retrospective denials after a service has already been preauthorized. There are also a crop of new state laws seeking to regulate the use of artificial intelligence in prior authorization decision-making.

Meanwhile, prior authorization bills introduced this year across the country, including in Kentucky, Missouri, and New Jersey, have been supported by politicians from both parties.

“Republicans in conservative states see health care as a vulnerability for the midterm elections, and so, unsurprisingly, you’ll see some action on this,” said Robert Hartwig, a clinical associate professor of risk management, insurance, and finance at the University of South Carolina. “They realize that they’re not really going to get much action at the federal level given the degree of gridlock we’ve already seen.”

Last summer, the Trump administration announced a pledge signed by dozens of health insurers vowing to reform prior authorization. The insurers promised to reduce the scope of claims that require preapproval, decrease wait times, and communicate with patients in clear language when denying a request.

Consumers, patient advocates, and medical providers have expressed skepticism that companies will follow through on their promises.

Becky Tennant is skeptical, too. That’s why she advocated for the West Virginia bill.

“Families should not have to beg, appeal, or go public just to access time-sensitive care,” she told lawmakers. Tennant, who sees the bill’s passage as bittersweet, said she thought her husband would have been proud.

During Eric’s final hospital stay, Tennant recalled, right before he was discharged to home hospice care, she asked him whether he wanted her to keep fighting to change the state agency’s prior authorization process.

“‘Well, you need to at least try to change it,’” she recalled her husband saying. “‘Because it’s not fair.’”

“I told him I would keep trying,” she said, “at least for a while. And so I am keeping that promise to him.”

—–

NBC News health and medical unit producer Jason Kane and correspondent Erin McLaughlin contributed to this report. KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.

The post After Man’s Death Following Insurance Denials, West Virginia Tackles Prior Authorization appeared first on Medika Life.

Health systems are not stepping into artificial intelligence from a place of calm or control. In the United States, spending now exceeds $4.5 trillion, with a significant share tied up in administrative work that adds complexity more than clarity. Clinicians are caring for more patients, navigating more data and making more decisions under pressure than ever before. The system is stretched. Artificial intelligence is entering at a moment when change is no longer a choice.

The discussion drew on the experience of three leaders who are not observing this shift. They are guiding it. Hal Wolf leads HIMSS, influencing digital health policy and implementation across more than 100 countries. Isaac Kohane, MD, PhD, Chair of Biomedical Informatics at Harvard Medical School, has spent four decades defining how data informs clinical care. Ran Balicer, MD, Chief Innovation Officer at Clalit Health Services, operates within one of the world’s most integrated health systems, where data and care are aligned across generations.

These are not just star panelists. They are system-wide architects.  What emerged from the hour-long conversation was not what artificial intelligence can do. It was a recognition that it is already doing more than most systems are prepared to guide and govern.

Dr. Kohane captured the tension immediately. “I think that we have to worry about the fact that we’re going both too slow and too fast.”

That statement reflects a reality many leaders feel but rarely express. Governance takes time because it must. Patient safety, validation and accountability require structure. Practice moves in real time. Clinicians do not have the luxury of waiting for perfect systems.

“They’re so desperate to do right by their patients to use other resources,” Dr. Kohane adds.

That instinct is not a weakness. It reflects a commitment to doing what is right for the patient. When clinicians turn to external AI tools, they are seeking clarity, speed, and confidence in their decisions. Artificial intelligence is already present at the point of care, shaping how physicians assess information, validate thinking, and move forward. The system is not adopting AI. The system is catching up.

This creates a condition that is difficult to measure and even harder to manage. Different clinicians use different ChatGPT platforms. Those tools produce different answers. Different assumptions shape those answers. Over time, consistency erodes. The system begins to operate with multiple definitions of truth (and the risk of varied outcomes).

Dr. Kohane’s warning is not about misuse. It is about misguided permanence. “The worst outcome will be if the worst parts of medicine get concrete poured over it, by AI.”

Artificial intelligence does not fix a system; without leadership, it accelerates the integration of incorrect assumptions. If workflows are inefficient, they become more efficiently inefficient. If bias exists in data, it becomes more precise. If fragmentation defines care, it scales.

This is not a failure of technology. It is a mirror held up to system-wide leadership.

Hal Wolf, among the health sector’s leading policy and operational voices, grounded this moment in proven experience. Health care has seen this pattern before. When internet connectivity entered hospitals, clinicians moved faster than governance. They created access where it was needed. Systems responded later. Risks were discovered after adoption.

Artificial intelligence now follows that same trajectory, though at far greater speed and with far greater consequences. Web connectivity gave quick access to information. Artificial intelligence influences how that information is interpreted and acted upon.

“We have to go faster,” Mr. Wolf said. “But there needs to be structure around it.”

That is the leadership challenge of this moment. Speed without structure creates exposure. Structure without speed creates irrelevance. The tension between the two is not something to resolve. It is something to manage continuously.

The industry has predictably responded to artificial intelligence. It has started where risk is lowest and return is clearest. Documentation, scheduling and revenue cycle optimization have become the entry points. These applications reduce burden and improve efficiency. They are necessary. However, they are not transformational.

The shift occurs when artificial intelligence moves into clinical decision-making. At that point, the question is no longer whether the system works. The question becomes whether it should be trusted.

Who owns a decision informed by an algorithm? How is accuracy validated? What happens when a clinician disagrees with a recommendation? These are not technical questions. They are questions of accountability. Artificial intelligence does not assume responsibility. It does not carry consequence. That remains with leadership.

Dr. Balicer reframed the conversation, shifting how the room thought about artificial intelligence. “There’s no such thing as AI neutrality. Algorithms are just opinions embedded in code.”

That insight is easy to acknowledge and difficult to operationalize. Every model reflects choices. What data is included? What outcomes are prioritized? What trade-offs are accepted? Those decisions are embedded in the system, shaping how it interprets information.

When a health system adopts an AI tool, it is not simply implementing technology. It is adopting a perspective.

At Clalit Health Services, alignment across payer and provider creates a system where priorities are consistent. Even there, external AI models introduce new assumptions. Those assumptions may not align with the system’s goals. If leadership does not define its own values, it inherits someone else’s.

This becomes real in proactive care. Artificial intelligence enables systems to identify patients at risk before they present. It allows for earlier intervention, often improving outcomes.

It also creates a new kind of pressure. “The toughest choice is what not to do,” Dr. Balicer said.

That statement deserves more attention than it receives. Health care has been built around responding to need. Artificial intelligence introduces the ability to anticipate it. When every patient can be flagged, every risk predicted and every intervention suggested, the system is no longer constrained by insight. It is constrained by capacity.

Artificial intelligence expands what can be done. It does not expand who can do it. Leadership becomes the act of choosing who does what based on validated data.

There is a moment that captures this shift. Imagine a primary care physician starting the day not with a schedule of patients who have called for appointments, but with a list generated by AI identifying individuals who are likely to experience clinical complications in the next six months. Some will develop chronic conditions. Some will require hospitalization. Some can be helped now – preventively.

The physician cannot see them all. Artificial intelligence expands what is possible. Leadership decides what is essential and permissible.

The industry often responds to complexity with activity. Organizations pilot, test and explore. They engage broadly without committing deeply. This creates motion. It rarely creates progress. Pilots are nothing more than experiments. At some point, leadership must decide what to scale, what to stop and what defines value.

Hal Wolf grounded the conversation in discipline. Without a defined, shared objective, effort becomes noise. Pilots create learning, though they often avoid decision-making. Leadership requires clarity. What problem are we solving? What outcome defines success? What are we willing to prioritize? Without those answers, artificial intelligence adds another layer of complexity to an already complex system.

Dr. Kohane brought the conversation back to the discipline of leadership. It cannot remain abstract. It must be informed by experience.

“Go and pay a few bucks and use three or four of the models… get a feel for what this does,” Dr. Kohane advised.

That is not a call for technical fluency. It is a call for leadership proximity. Leaders cannot guide what they do not understand. Artificial intelligence does not behave consistently across models. It produces different answers, shaped by different assumptions. Without direct engagement, those differences remain hidden, and leadership becomes removed from the very decisions it is responsible for guiding.

This is where many organizations hesitate. Artificial intelligence feels complex and complexity invites delegation. At this moment, delegation creates distance. Leadership is required to move closer, not further away.

Artificial intelligence is not reducing the role of leadership. It is redefining it.

This is not a gradual transition. It is already underway. Artificial intelligence is embedded in workflows, shaping decisions and influencing behavior in real time. The system is adapting whether leadership is ready or not.

The question is no longer whether artificial intelligence will shape the future of health. It will. The question is whether leadership will shape how it is applied.

Artificial intelligence will not fix health. It will scale whatever we allow it to touch. The question is whether it will scale what is best in health or what we have yet to fix.

The post AI Will Not Fix Health Care – Leadership Might appeared first on Medika Life.

Primary care continuity allows physicians to develop a longitudinal awareness that no episodic encounter or health tech tool can replicate. Over time, physicians learn what is normal for each patient and what represents meaningful clinical change. Subtle physiological shifts, early symptoms or emerging risk factors appear not as isolated data points from a blood exam, but as part of a social narrative unfolding across time. Early recognition allows earlier intervention, often before disease takes its profound toll.

Clinical evidence confirms the protective effect of continuity. It’s not a matter of opinion. A systematic review published in BMJ Open found that patients with sustained continuity of care had significantly lower mortality than those with fragmented care. Continuity did not just improve satisfaction; it altered survival. The physician who knows the patient can detect disease earlier and guide care more effectively.

Listening allows physicians to detect patterns that laboratory values alone cannot explain. Patients share information differently when they believe that their physician understands them and remembers their history. This sustained awareness allows physicians to identify emerging illnesses without relying solely on reactive diagnostics. Continuity transforms listening into clinical intelligence and a deeper care partnership.

In Healing the Sick Care System: Why People Matter, which has become a surprise Amazon bestseller, one insight repeatedly emerges: patients do not seek care only for treatment; they seek reassurance that someone who knows them is guiding their journey. Physicians who listen across time accumulate knowledge that cannot be captured in a chart alone. That memory allows earlier recognition, more accurate interpretation, and wiser intervention. Healing begins in that continuity of understanding.

Transactional Care Solves Symptoms but Sacrifices Understanding

Health has, for some time, been undergoing a structural shift toward transactional encounters. Walk-in clinics, urgent care centers, and virtual platforms provide speed and accessibility that patients value. These models address immediate symptoms efficiently and fill important gaps in care delivery. Accessibility has improved, yet continuity has weakened.

Transactional medicine treats episodes rather than trajectories. Each encounter begins without the benefit of longitudinal understanding. Clinical decisions are made with time-stamp specific knowledge of how symptoms emerged or how physiology has changed over time. Care becomes reactive rather than interpretive.

Research demonstrates the consequences of this fragmentation. Studies published in the Annals of Family Medicine show that sustained primary care continuity reduces hospitalizations and lowers healthcare expenditures. Early recognition prevents complications that require more invasive, costly interventions. Fragmentation delays recognition and increases clinical risk.

In fact, physicians in the vanguard of building relationships encourage their patients to ask questions.  In their co-authored book Let Patients Help! A “Patient Engagement” handbook – how doctors, nurses, patients and caregivers can partner for better care by “e-Patient Dave” deBronkart with Daniel Z. Sands, MD, MPH, the founder of the Society for Participatory Medicine, offer 10 suggestions that clinicians say to encourage patient engagement.

This shift also alters how patients engage with care. Connections that develop over time can be lost quickly when continuity disappears. Patients become consumers navigating isolated services rather than partners guided across time. The clinical relationship weakens, and with it the interpretive depth that makes prevention possible.

Health systems globally recognize the value of continuity. The Organization for Economic Co-operation and Development (OECD), a Paris-based international organization that promotes policies to improve economic and social well-being globally, reports that hospital admissions for chronic diseases, often preventable through effective primary care, account for a substantial share of healthcare utilization. Systems that preserve physician-led primary care continuity achieve better outcomes and greater efficiency. Relationship stabilizes care.

Innovation Requires Connection to Fulfill Its Potential

This shift toward transactional care carries life-threatening implications that extend far beyond the patient experience. It also directly affects whether health innovation fulfills its promise or becomes a compensatory tool addressing fragmentation. Innovation depends on context to generate meaningful insight. Context emerges through continuity. That context can devalue life-saving innovations.

Artificial intelligence, predictive analytics, and remote monitoring technologies are designed to detect patterns across time. These tools require longitudinal clinical awareness to distinguish meaningful change from statistical variation. Physicians who know their patients can interpret innovation correctly and act earlier. Innovation becomes transformative when anchored in relationship.

Fragmented care weakens this interpretive capacity. Data collected across disconnected encounters lacks coherence. Predictive tools lose precision when longitudinal context is absent. Innovation becomes reactive, identifying disease after symptoms emerge rather than predicting disease before it develops.

Technology achieves its highest value when it extends the physician’s ability to listen and observe. Remote monitoring allows earlier recognition of physiological change. Predictive analytics strengthens preventive intervention. Innovation amplifies continuity when guided by sustained physician leadership.

Team-based primary care models reflect this principle. Nurse practitioners and physician assistants expand access while physician leadership preserves interpretive continuity. Research published in Medical Care Research and Review confirms that coordinated team-based care maintains strong clinical outcomes. Physician oversight ensures that innovation remains integrated within longitudinal care. It also improves health professional job satisfaction and reduces burn-out.

Innovation cannot replace the relationship at the center of medicine. Algorithms detect patterns but do not understand meaning, and they do not strengthen physician/patient ties. Devices collect data, but do not know the patient behind the data. Physicians translate information into guidance by integrating technology with human understanding.

The future of health innovation depends on preserving continuity between patient and physician. Technology deployed within sustained relationships strengthens prevention and improves outcomes. Technology deployed within fragmented systems often compensates for structural weakness rather than transforming care. Continuity determines whether innovation fulfills its promise.

Health systems now face a defining moment. Transactional care offers speed and convenience. Relational care offers understanding and prevention. Innovation will achieve its full potential only when it strengthens the continuity that allows physicians to listen, learn, and guide patients across time.

Healing begins with being heard. Health technology succeeds when it helps physicians listen more deeply and act more wisely in the service of the people who entrust them with their care.

The post How Transactional Medicine Threatens the Future of Your Health appeared first on Medika Life.

The country’s trajectory has been building for years. A fast-growing middle-income population, rising chronic disease burden, and expanding health infrastructure have created both demand and urgency. What is changing now is the environment in which innovation can move, driving faster approvals, a culture of collaboration, digital infrastructure and a government signaling policy readiness to engage global partners in shaping the next era of medicine.

The economic momentum is significant. The Indian health ecosystem has expanded from roughly $372 billion in 2023 to $638 billion in 2025, making it one of the fastest-growing major health markets in the world. The broader industry is expected to exceed $610 billion by 2026, fueled by rising insurance coverage, expanding hospital infrastructure, and growing demand for chronic disease management. Health growth in India continues at approximately 10–12 percent annually, well above the growth rates typical of mature markets, reflecting both rising access and structural transformation.

BIOAsia 2026 reflects this inflection point. The global gathering in Hyderabad, themed “TechBio Unleashed: AI, Automation & the Biology Revolution,” highlights the (bio)convergence of biology, data, and intelligent systems reshaping health worldwide. Organizers emphasize that the meeting aims to drive health transformation and reinforce India’s position as a leading global life sciences force. For multinational innovators, the message is increasingly clear: India is not only where innovation is deployed; it is also where it is developed. It is where innovation is increasingly defined. India has become a go-to market for multinational enterprises.

Policy Signals and Market Scale: From Opportunity to Strategic Partnership

India’s regulatory and policy environment is evolving in ways that matter deeply to multinational innovators. One pivotal shift came with the country’s decision to allow certain medicines approved in specified developed markets to launch without local clinical trials, a move designed to accelerate patient access while aligning more closely with global regulatory science. This policy shift reflected confidence in international data, a commitment to innovation, and recognition that faster access must remain central to national health strategy.

The scale of India’s pharmaceutical and life sciences market reinforces this transformation. The pharmaceutical sector reached approximately $68 billion in 2025 and is projected to grow to more than $170 billion during the next decade, driven by expanding middle-income demand and strong domestic manufacturing. India already supplies roughly one-fifth of the world’s generic medicines. It produces the majority of global vaccines by volume, positioning the country as a central player in global health supply chains.

As Aman Gupta of SPAG/FINN wrote in Medika Life, “India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants.” His observation reinforces a central reality for multinational innovators: India’s policy environment is increasingly designed not only to welcome global participation, but to encourage long-term strategic partnership in building the future of healthcare.

Investment trends tell the same story. Health and pharmaceutical private equity and venture investments have reached multi-billion-dollar levels annually. At the same time, India’s contract drug development and manufacturing sector is projected to exceed $22 billion within the next decade. These dynamics position India as a growth market and as a strategic partner across the innovation lifecycle from discovery and clinical development to manufacturing and global distribution.

Shakthi Nagappan, CEO of Telangana Life Sciences Foundation, captured this moment clearly, noting that BIOAsia arrives at a time when technology and biology are redefining healthcare and creating “unprecedented opportunities for innovation, investment, and impact.” The language reflects partnership rather than transaction, a signal that India is moving from market opportunity to strategic collaboration.

Digital Infrastructure, BIOAsia and the Multinational Innovation Imperative

India’s digital transformation may be its most potent catalyst for long-term health innovation. Unlike many mature systems, the country is building a national-scale digital health infrastructure designed to connect patients, providers, and health systems across a population of more than 1.4 billion people, with a rising middle class of 400 million.

The Global Digital Health Market is projected to grow from USD 288.55 billion in 2024 to USD 2,688 billion by 2035, expanding at a CAGR of 22.55% during 2025–2035. This surge is driven by the rapid adoption of AI-powered diagnostics, telemedicine, wearable devices, and data analytics solutions that are revolutionizing patient care and operational efficiency worldwide.

Hundreds of millions of citizens are already using digital health services, including telemedicine, electronic prescriptions, and remote care. The Ayushman Bharat Digital Mission is creating an interoperable national health ecosystem, enabling secure health records, improved care coordination, and population-scale data infrastructure that supports research, real-world evidence, and precision health.

For multinational companies, this digital backbone creates a uniquely strategic environment, enabling large-scale clinical research, faster pharmacovigilance, AI-supported health insights, and rapid deployment of innovation across diverse populations. India’s digital infrastructure is not simply modernizing health delivery. It is enabling national-scale transformation.

BIOAsia sits at the center of this conversation and convergence. The gathering reflects India’s ambition to lead at the intersection of biology, artificial intelligence, and scalable innovation. Leaders from industry, government, and science convene not only to discuss growth but to shape the next phase of global life sciences, where biology, data, and digital systems converge to influence global health.

One conference panel, among the many high-powered sessions, brings together global leaders in advanced therapeutics to explore how next-generation modalities are moving from discovery to scalable care. Panelists across biopharma, translational science, and hospital systems are examining progress in cell and gene therapies, mRNA, and radiopharmaceuticals, underscoring that innovation now depends as much on manufacturable scale and delivery as on scientific breakthrough. India’s expanding capabilities in clinical research and bioprocessing strengthen its role as a key partner in advancing next-generation therapies.

For multinational innovators, the implications are clear. Engagement in India now extends beyond commercialization. It calls for collaboration in research, investment in digital and scientific ecosystems, alignment with national health priorities and partnership in strengthening health delivery.

India’s Strategic Role in Global Health Innovation

India’s rise in global health innovation reflects the alignment of policy, market growth, digital infrastructure, and scientific capability forces that together are reshaping where and how healthcare innovation occurs.

For multinational companies, India now represents a full-spectrum innovation environment. It is a place to conduct clinical research across diverse populations, scale manufacturing and supply chains, deploy digital health at a national scale, and co-develop solutions addressing both local and global health challenges. Increasingly, India is not simply a recipient of innovation developed elsewhere. It is becoming a co-creator of next-generation health.

This shift changes the strategic equation. Market entry alone is no longer sufficient. Meaningful engagement requires partnership with policymakers, regulators, scientists, health providers, and digital health ecosystems. Organizations that invest in collaboration, align with national health priorities, and contribute to strengthening healthcare systems are most likely to succeed in India’s evolving landscape.

BIOAsia sets the stage for this transformation. It is more than a conference. It is a convergence of global health ambition, scientific capability, and policy momentum. The conversations taking place in Hyderabad mirror a broader reality: the geography of health innovation is expanding, and India is now central to its future.

For global health innovators, the question is no longer whether India matters. The question is how deeply they choose to engage in shaping what comes next.

The post India: The Growing Focal Point for Health Innovation appeared first on Medika Life.

Many private-sector investors are considering health in Africa. Maybe that’s no surprise; the African Development Bank says the Continent could almost double its GDP if health were better. Robert Appelbaum, though, thinks that many are interested in what Africa might export as well as the potential unlocked at home.

Appelbaum has advised multinational pharma companies through the most difficult episodes of the past three decades including the disputes over HIV medicines patents and the transfer of technology to African producers. He also provides legal and business counsel to billionaires who are household names. “Today, investors are looking at the African Continental Trade Agreement (AFCTA) and the commercialisation of African drugs and devices for use across the world,” he told me. “The AFCTA is making Africa into a legitimate manufacturing hub for the full gamut of manufacture from API [active pharmaceutical ingredients] through to fill and finish, whereas in the past we have been in the business of fill and finish,” he added.

The day before we spoke I had been to see the Biomedical Research Institute at Stellenbosch. It houses a network of 26 BSL-3 — highly secure — laboratories to handle infectious diseases samples. There are probably a third as many BSL-3 labs at Stellenbosch alone as there in all of China. The Biobank in the same facility has space for up to seven million samples and provides an exceptionally rapid way of looking back at the evolution of disease outbreaks. It was designed to allow another seven million to be stored when needed. To give an idea of how massive this is, the largest biobank in China can hold 10 million samples and the largest human biobank in Europe can keep 20 million. Maybe the most impressive statistic is that the Stellenbosch institute was completed for about €65 million, a fraction of what it would have cost in Europe.

Cost is not Africa’s only advantage: it has the kind of frugal innovation that hard-pressed European and American health systems need. “There is a huge amount of work taking place — more in devices and technology than in drug discovery. Africans are very innovative at creating for ourselves what does not already exist,” Appelbaum said. These are exactly the areas in which slow first-world innovation is holding back medicine: commissions on antimicrobial resistance assumed point-of-care diagnostics would by now have been able to differentiate between viral and bacterial illnesses and between different kinds of infectious bacteria. They cannot.

Pre-history gives Africa another advantage. As humans spread across the globe from Africa, we lost genetic diversity. It’s said that today there is more genetic diversity within Mozambique than between people in South Asia and people in Europe. In that vast genetic storehouse are hidden undiscovered clues to resisting and treating disease — clues that can be transformed into prevention, diagnosis and treatment by health innovators. As Africans have more access to health services, those genetic assets and liabilities will become more and more evident and accessible. This is a key aspect of the African Human Genome project and of South African agreements with commercial entities such as Illumina and MGI.

To spot the real life implications of these genetic patterns, to find population clusters and to identify possible genetic outliers, a country needs easy, secure access to massive numbers of records. The United Kingdom sees this as a competitive advantage for its four national health services while France’s La poste, the nation’s post office, is bringing together over 40 million patients’ referrals, visit reports and test results. These and other developed world efforts, though, are having to retrofit national analytical frameworks onto multiple old data systems and to pry data loose from academics and care systems with strong proprietorial instincts. African countries are building new national data systems from the bottom up with integration and analysis as part of the original design. Appelbaum thinks that Africa may again leapfrog over Western competitors, just as it did by introducing modern mobile telephony and mobile payment systems while legacy system owners slowed down adoption in Europe and the Americas.

Many think that Oracle has already honed in on the opportunity. It has partnered with the Tony Blair Institute to introduce vaccine tracking systems in Ghana, Rwanda and Sierra Leone and to promote them Continent-wide. Given the vast effort that Oracle continues to put into developing a nationwide repository of health records in the USA and the Gulf states, many see its efforts in Africa as a test run for much broader and more ambitious national health databases. African countries are not waiting. Kenya’s Afya Yangu platform is already operational in a third of the nation’s counties and provides portable individual records including medical history, prescriptions, lab results, and appointments for three million users. South Africa faces some of the same challenges as Europe in unifying or supplanting existing systems but its Health Patient Registration System has registered over 57 million patients across more than 3,000 facilities as a foundation for portable electronic health records. Africa’s health data is a vast opportunity which governments will need to use as the basis for investment.

Private sector health investors are indispensable to Africa, Appelbaum thinks. In the US and Europe, they find far more R&D than governments and foundations combined; that must be the pattern in Africa if the Continent is to not just meet its own health needs but to develop innovations for the world.

The post Why Sophisticated Investors Really Care about Health in Africa appeared first on Medika Life.

I have spent more than 30 years in healthcare with one consistent mission: helping people sustain and improve their lives. That mission has guided my work across large pharmaceutical companies, entrepreneurial startups, and academic institutions. It has shaped how I view innovation—not as a luxury, but as a necessity.

We often speak about healthcare innovation as if it exists in a vacuum. It does not. Innovation only matters if patients can access it, understand it, and afford it. Today’s system too often breaks that chain.

The U.S. healthcare system has evolved to prioritize risk management over prevention, short-term cost containment over long-term health, and utilization controls over patient outcomes. The consequences are real. Breakthrough therapies are delayed or denied. Preventive medicines are underused. Patients are left navigating complexity at the very moment they are most vulnerable.

However, innovation has repeatedly proven it can change the trajectory of disease—and lives—when it reaches patients.

Earlier in my career, I had the opportunity to help build Claritin into a household name. What made Claritin transformational was not just the molecule, but access. Non-sedating allergy relief allowed people to function—to work, learn, drive, and live daily life without compromise. We paired scientific innovation with brand-building, education, and emerging digital tools to enable patients to engage with their care in new ways. That experience taught me something enduring: innovation fails when it remains trapped behind complexity.

As digital channels emerged, I saw how virtual access could democratize care. Early online refill capabilities and digital front doors were not about marketing. They were about meeting patients where they were. Innovation is not only what happens in the lab; it is how solutions are delivered in the real world.

More recently, my work in cardiovascular and preventive medicine has reinforced this belief. Cardiovascular disease remains the leading cause of death globally, yet preventive innovation often struggles most to gain access. When therapies reduce future heart attacks, strokes, and hospitalizations—but do not show immediate cost offsets within narrow budget windows—they face resistance. This is actuarial logic colliding with human biology.

But prevention works. Inflammation matters. Long-term risk reduction matters. Helping people avoid catastrophic events enables them to remain productive, engaged, and present in their lives and with their families. The value of that outcome is difficult to capture on a quarterly balance sheet, but it is undeniable.

Innovation also matters because healthcare is not static. Populations are aging. Chronic disease is rising. Demand for care will only increase. Without continued pharmaceutical innovation—new mechanisms, better tolerability, improved adherence—we risk managing decline rather than enabling vitality.

Critics often frame innovation and affordability as opposing forces. They are not. The real tension lies between short-term system incentives and long-term societal benefit. When access to effective therapies is delayed or denied, costs do not disappear. They shift—reappearing as hospitalizations, disability, lost productivity, and diminished quality of life.

I have worked inside large organizations, small startups, and everything in between. I have seen how difficult it is to bring a medicine from concept to patient—and how fragile that final step of access can be. That is why innovation must be paired with thoughtful policy, modernized reimbursement, and a patient-centered view of value.

Healthcare should not be about simply surviving longer. It should be about living better for longer. Medical innovation, particularly in pharmaceuticals, plays a central role in making that possible. Even in a system burdened by complexity and constraints, innovation remains one of our strongest tools for advancing healthcare.

After three decades, my belief has not changed: when science, access, and mission align, lives improve. That is worth fighting to achieve.

The post Medical Innovation Still Matters—Even When the System Makes It Hard appeared first on Medika Life.